Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study. Read more about Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Read more about Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.
Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors. Read more about Hyperpolarized 13C magnetic resonance metabolic imaging: application to brain tumors.
Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing. Read more about Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Read more about Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma.
Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide. Read more about Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Read more about A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Read more about A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Read more about Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. Read more about Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.
